Toggle Main Menu Toggle Search

Open Access padlockePrints

Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice

Lookup NU author(s): Dr Paul Brennan

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© The Author(s) 2024. Background: The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice. Methods: To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16th of May 2023, with the aim of establishing best practice guidelines. Results: Using a pre-workshop survey followed by structured discussion and in-meeting polling, we achieved consensus for UK best practice in use of CanRisk in making recommendations for breast cancer surveillance, eligibility for genetic testing and the input of available information to undertake an individualised risk assessment. Conclusions: Whilst consensus recommendations were achieved, the meeting highlighted some of the barriers limiting the use of CanRisk in clinical practice and identified areas that require further work and collaboration with relevant national bodies and policy makers to incorporate wider use of CanRisk into routine breast cancer risk assessments.


Publication metadata

Author(s): Tsoulaki O, Tischkowitz M, Antoniou AC, Musgrave H, Rea G, Gandhi A, Cox K, Irvine T, Holcombe S, Eccles D, Turnbull C, Cutress R, Archer S, Hanson H, Andreou A, Badran A, Bartlett M, Berlin C, Binysh K, Brennan P, Cleaver R, Corbett G, Davidson R, DeSouza B, Evers R, Ficorella L, Fitzgerald S, Forman A, Gilbert F, Gold R, Greville-Heygate S, Hamilton S, Hammond C, Hart R, Hawkes L, Hayward J, Holliday D, Howell A, Hutchison G, Jenkins J, Jewell R, Kavanaugh G, Kemp Z, Kiesel V, Kumar A, Lalloo F, Miedzybrodzka Z, Murray J, Nisbet S, Ogunleye D, Paramasivam A, Searle C, Shaw A, Sheridan E, Side L, Smith K, Speight B, Teh W, Thorpe E, Whaite A, Wilkinson L, Wilkinson S, Woodward ER, Youngs A

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2024

Volume: 130

Pages: 2027-2036

Print publication date: 29/06/2024

Online publication date: 04/06/2024

Acceptance date: 21/05/2024

Date deposited: 19/06/2024

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Springer Nature

URL: https://doi.org/10.1038/s41416-024-02733-4

DOI: 10.1038/s41416-024-02733-4

Data Access Statement: The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
C61296/A27223
Cancer Research UK grant PPRPGM-Nov20\100002
Cancer Research CRUK Catalyst Award, CanGene-CanVar
MRC MR/X502844/1
National Institute for Health and Care Research Exeter Biomedical Research Centre (NIHR203320)
NIHR Cambridge Biomedical Research Centre (NIHR203312)

Share